600196 复星医药
已收盘 01-29 15:00:00
资讯
新帖
简况
复星医药（600196）披露控股子公司药品获临床试验批准的公告，1月27日股价下跌1.7%
证券之星 · 01-27 22:52
复星医药（600196）披露控股子公司药品获临床试验批准的公告，1月27日股价下跌1.7%
复星医药最新公告：聘任孟凌媛为公司副总裁
证券之星 · 01-27 17:32
复星医药最新公告：聘任孟凌媛为公司副总裁
复星医药：复宏汉霖及子公司药品临床试验获批
财中社 · 01-27 17:25
复星医药：复宏汉霖及子公司药品临床试验获批
复星医药控股股东复星高科技质押率降至49.54%
中金财经 · 01-26
复星医药控股股东复星高科技质押率降至49.54%
每周股票复盘：复星医药（600196）拟分拆复星安特金赴港上市
证券之星 · 01-25
每周股票复盘：复星医药（600196）拟分拆复星安特金赴港上市
复星医药（600196）股东上海复星高科技(集团)有限公司质押3200万股，占总股本1.2%
证券之星 · 01-23
复星医药（600196）股东上海复星高科技(集团)有限公司质押3200万股，占总股本1.2%
复星医药：近年来公司持续在创新研发等多维度践行国际化战略
证券日报 · 01-22
复星医药：近年来公司持续在创新研发等多维度践行国际化战略
复星医药重酒石酸去甲肾上腺素注射液药品注册申请获批准
美股速递 · 01-22
复星医药重酒石酸去甲肾上腺素注射液药品注册申请获批准
复星医药最新公告：分拆所属子公司复星安特金至香港联交所主板上市获董事会批准
证券之星 · 01-22
复星医药最新公告：分拆所属子公司复星安特金至香港联交所主板上市获董事会批准
复星医药最新公告：控股子公司药品重酒石酸去甲肾上腺素注射液获注册批准
证券之星 · 01-22
复星医药最新公告：控股子公司药品重酒石酸去甲肾上腺素注射液获注册批准
复星医药：控股子公司药品获临床试验批准
人民财讯 · 01-20
复星医药：控股子公司药品获临床试验批准
复星医药（600196）披露控股子公司部分境内未上市股份申请全流通完成中国证监会备案，01月19日股价下跌0.54%
证券之星 · 01-19
复星医药（600196）披露控股子公司部分境内未上市股份申请全流通完成中国证监会备案，01月19日股价下跌0.54%
复星医药（600196）公司公告控股子公司激励计划实施进展，1月14日股价下跌0.39%
证券之星 · 01-14
复星医药（600196）公司公告控股子公司激励计划实施进展，1月14日股价下跌0.39%
复星医药子公司注射用乳糖酸红霉素注册申请获受理
北京商报 · 01-14
复星医药子公司注射用乳糖酸红霉素注册申请获受理
每周股票复盘：复星医药（600196）参投基金完成备案
证券之星 · 01-11
每周股票复盘：复星医药（600196）参投基金完成备案
复星医药富马酸福替尼胶囊药品注册申请获国家药监局受理
美股速递 · 01-08
复星医药富马酸福替尼胶囊药品注册申请获国家药监局受理
复星医药(600196.SH)控股子公司药品注册申请获受理
智通财经 · 01-08
复星医药(600196.SH)控股子公司药品注册申请获受理
复星医药（600196）披露参与设立之私募股权投资基金进展，1月5日股价上涨2.94%
证券之星 · 01-05
复星医药（600196）披露参与设立之私募股权投资基金进展，1月5日股价上涨2.94%
14亿元接盘“不良资产” 复星医药被质疑“豪赌”
经济参考报 · 01-05
14亿元接盘“不良资产” 复星医药被质疑“豪赌”
每周股票复盘：复星医药（600196）SRT-007启动Ⅰ期临床，研发已投3219万元
证券之星 · 01-02
每周股票复盘：复星医药（600196）SRT-007启动Ⅰ期临床，研发已投3219万元
加载更多
公司概况
公司名称：
上海复星医药(集团)股份有限公司
所属行业：
医药制造业
上市日期：
1998-08-07
主营业务：
上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。
发行价格：
7.15
{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":27.12,"timestamp":1769670001000,"preClose":26.96,"halted":0,"volume":28938355,"delay":0,"changeRate":0.0059,"floatShares":2118000000,"shares":2670000000,"eps":1.2293,"marketStatus":"已收盘","change":0.16,"latestTime":"01-29 15:00:00","open":26.87,"high":27.13,"low":26.6,"amount":777000000,"amplitude":0.0197,"askPrice":27.13,"askSize":604,"bidPrice":27.12,"bidSize":10,"shortable":0,"etf":0,"ttmEps":1.2293,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1769736600000},"marketStatusCode":5,"adr":0,"adjPreClose":26.96,"symbolType":"stock","openAndCloseTimeList":[[1769650200000,1769657400000],[1769662800000,1769670000000]],"highLimit":29.66,"lowLimit":24.26,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2670429325,"isCdr":false,"pbRate":1.51,"roa":"--","peRate":22.061336,"roe":"5.3%","epsLYR":1.04,"committee":-0.333333,"marketValue":72422000000,"turnoverRate":0.0137,"status":0,"hkstockBrief":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":20.98,"timestamp":1769674106003,"preClose":20.72,"halted":0,"volume":2737000,"delay":0,"premium":"-31.16"},"floatMarketCap":57453000000},"requestUrl":"/m/hq/s/600196","defaultTab":"news","newsList":[{"id":"2606873733","title":"复星医药（600196）披露控股子公司药品获临床试验批准的公告，1月27日股价下跌1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606873733","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606873733?lang=zh_cn&edition=full","pubTime":"2026-01-27 22:52","pubTimestamp":1769525535,"startTime":"0","endTime":"0","summary":"截至2026年1月27日收盘，复星医药报收于27.68元，较前一交易日下跌1.7%，最新总市值为739.17亿元。近日，复星医药发布《关于控股子公司药品获临床试验批准的公告》。公告显示，公司控股子公司复宏汉霖收到国家药监局批准，同意注射用HLX43联合HLX07及斯鲁利单抗注射液用于晚期实体瘤治疗的临床试验。HLX43、HLX07及斯鲁利单抗均为自主研发或合作开发的创新型生物药，目前均处于临床试验阶段。全球范围内尚无同类联合用药方案获批上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700042306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK1191","BK0096","BK0175","BK1515","BK0187","BK0012","BK0196","BK1593","02196","BK0028","BK0183","BK0060","BK0239","600196"],"gpt_icon":0},{"id":"2606020402","title":"复星医药最新公告：聘任孟凌媛为公司副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2606020402","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606020402?lang=zh_cn&edition=full","pubTime":"2026-01-27 17:32","pubTimestamp":1769506366,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，公司第十届董事会第二十三次会议同意聘任孟凌媛为公司副总裁，任期自2026年1月26日起至本届董事会任期届满之日止。孟凌媛曾任普华永道会计师事务所经理、高级经理，复星高科技审计高级总监等职务，拥有中国注册会计师资质。截至2026年1月26日，孟凌媛未持有公司股份，与公司不存在关联关系，也不存在不得担任上市公司高级管理人员的情形。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700029716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0096","BK0183","BK0239","BK0175","BK0188","02196","BK0196","BK1191","BK1593","BK0187","BK1515","600196","BK0060","BK0012"],"gpt_icon":0},{"id":"2606202415","title":"复星医药：复宏汉霖及子公司药品临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2606202415","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606202415?lang=zh_cn&edition=full","pubTime":"2026-01-27 17:25","pubTimestamp":1769505958,"startTime":"0","endTime":"0","summary":"1月27日，复星医药（600196/02196）发布公告，公司的控股子公司复宏汉霖（02696）及其控股子公司获批同意注射用HLX43联合HLX07及斯鲁利单抗注射液用于晚期实体瘤治疗开展临床试验。截至2025年12月，公司及控股子公司现阶段针对该治疗方案的累计研发投入约为266万元。截至本公告日期，全球范围内尚无同类联合用药治疗方案获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601273632288439.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","HK0000320264.USD","HK0000306701.USD","02696","BK0187","BK0188","BK0096","BK0012","BK0175","BK0239","HK0000306685.HKD","BK0028","BK0060","BK0196","HK0000165453.HKD","BK1161","HK0000320223.HKD","BK0183","BK1593","02196","600196","BK1191"],"gpt_icon":0},{"id":"2606215878","title":"复星医药控股股东复星高科技质押率降至49.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606215878","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606215878?lang=zh_cn&edition=full","pubTime":"2026-01-26 17:14","pubTimestamp":1769418860,"startTime":"0","endTime":"0","summary":"中国经济网北京1月26日讯 复星医药 日前披露关于股东部分股份质押及解除质押的公告称，公司于2026年1月23日接到控股股东上海复星高科技(集团)有限公司的通知，其已将所持有的公司部分A股股份办理质押及解除质押手续。 复星高科技本次将3200万股股份质押给中国工商银行股份有限公司上海市长宁支行，质押期限自2026年1月22日至2028年1月26日，融资用途为偿还债务。该笔质押股份占复星高科技所持公司股份的3.33%，占公司总股本的1.20%。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202601/26/20260126961437.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202601/26/20260126961437.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260126/31972679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0175","02196","BK1515","BK0239","600196","BK0187","BK0196","BK0188","BK1191","BK0183","BK0028","BK1593","BK0096","BK0012","BK0060"],"gpt_icon":0},{"id":"2606234424","title":"每周股票复盘：复星医药（600196）拟分拆复星安特金赴港上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2606234424","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606234424?lang=zh_cn&edition=full","pubTime":"2026-01-25 01:54","pubTimestamp":1769277253,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，复星医药报收于27.57元，较上周的27.59元下跌0.07%。本周关注点来自公司公告汇总：复星医药拟分拆子公司复星安特金至香港联交所主板上市，已获董事会审议通过。本次分拆后，复星医药仍将保持对复星安特金的控制权，相关议案尚需提交股东会审议及监管机构批准。股本股东变化截至2026年1月22日，复星医药控股股东复星高科技持有公司961,424,455股，占总股本36.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500000431.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","BK0187","BK1593","02196","BK0188","BK0183","600196","BK0239","BK0196","BK0060","BK0175","BK1191","BK0096","BK1515"],"gpt_icon":0},{"id":"2605479403","title":"复星医药（600196）股东上海复星高科技(集团)有限公司质押3200万股，占总股本1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605479403","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605479403?lang=zh_cn&edition=full","pubTime":"2026-01-23 18:37","pubTimestamp":1769164670,"startTime":"0","endTime":"0","summary":"证券之星消息，复星医药1月23日公开信息显示，股东上海复星高科技(集团)有限公司向中国工商银行股份有限公司上海市长宁支行合计质押3200.0万股，占总股本1.2%。质押详情见下表：截止本公告日，股东上海复星高科技(集团)有限公司已累计质押股份4.76亿股，占其持股总数的53.52%。复星医药主营业务：制药、医疗器械与医学诊断、医疗健康服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300032243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0187","BK1593","02196","BK0188","BK0096","BK0183","600196","BK0196","BK0012","BK0028","BK1191","BK1515","BK0175","BK0060"],"gpt_icon":0},{"id":"2605491866","title":"复星医药：近年来公司持续在创新研发等多维度践行国际化战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2605491866","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605491866?lang=zh_cn&edition=full","pubTime":"2026-01-22 21:03","pubTimestamp":1769087023,"startTime":"0","endTime":"0","summary":"证券日报网讯1月22日，复星医药在互动平台回答投资者提问时表示，近年来，公司持续在创新研发、许可引进、生产运营及商业化等多维度践行国际化战略，提升运营效率，强化全球市场布局，并已主要覆盖美国、欧洲、非洲、印度和东南亚等海外市场。公司在欧盟市场的销售模式采用了多元化方式。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601223627658039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0196","BK1191","BK0183","BK0060","BK0175","BK1515","BK1593","BK0028","BK0096","600196","BK0239","BK0187","02196","BK0188","BK0012"],"gpt_icon":0},{"id":"1108542084","title":"复星医药重酒石酸去甲肾上腺素注射液药品注册申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1108542084","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108542084?lang=zh_cn&edition=full","pubTime":"2026-01-22 20:26","pubTimestamp":1769084773,"startTime":"0","endTime":"0","summary":"复星医药（600196）宣布，其重酒石酸去甲肾上腺素注射液的药品注册申请已获得监管部门批准。\n该药品获批将进一步丰富公司的心血管领域产品线，对提升市场竞争力具有积极意义。重酒石酸去甲肾上腺素作为临床常用急救药物，其上市将为患者提供更多治疗选择。\n此次获批体现了公司在创新药研发和注册申报方面的综合实力，也为未来业绩增长注入新动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600196","BK0188","BK0239","BK0175","BK0028","BK0196","BK0060","BK0012","BK0187","BK0183","BK0096"],"gpt_icon":0},{"id":"2605462947","title":"复星医药最新公告：分拆所属子公司复星安特金至香港联交所主板上市获董事会批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2605462947","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605462947?lang=zh_cn&edition=full","pubTime":"2026-01-22 18:10","pubTimestamp":1769076641,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，公司第十届董事会第二十二次会议审议通过关于分拆所属子公司复星安特金（成都）生物制药股份有限公司至香港联交所主板上市的议案。该议案包括分拆上市符合相关法律法规规定、首次公开发行H股股票方案、分拆上市预案以及分拆上市符合《上市公司分拆规则（试行）》等内容。公司表示，本次分拆上市符合相关法律法规及监管机构的要求，具备可行性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200030530.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0196","600196","BK0060","BK0239","BK0012","BK0096","BK0175","BK0188","BK1515","BK1593","BK0183","BK1191","BK0028","02196"],"gpt_icon":0},{"id":"2605462911","title":"复星医药最新公告：控股子公司药品重酒石酸去甲肾上腺素注射液获注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2605462911","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605462911?lang=zh_cn&edition=full","pubTime":"2026-01-22 18:09","pubTimestamp":1769076585,"startTime":"0","endTime":"0","summary":"复星医药公告称，公司控股子公司锦州奥鸿药业有限责任公司就重酒石酸去甲肾上腺素注射液的药品注册申请获国家药品监督管理局批准。该药品获批适应症包括急性低血压状态的血压恢复、心跳骤停的辅助治疗和心跳骤停复苏后的血压维持等。该药品为复星医药自主研发的化学药品，截至2025年12月，累计研发投入约为人民币874万元。该药品获批上市将进一步丰富复星医药的产品线，但具体销售情况可能受到多种因素影响，具有较大不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200030532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK0188","BK1515","BK0183","BK0028","BK1593","BK0187","BK0096","BK0196","BK0175","BK0060","600196","BK0239","02196","BK0012"],"gpt_icon":0},{"id":"2604119589","title":"复星医药：控股子公司药品获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2604119589","media":"人民财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604119589?lang=zh_cn&edition=full","pubTime":"2026-01-20 16:55","pubTimestamp":1768899334,"startTime":"0","endTime":"0","summary":"人民财讯1月20日电，复星医药(600196)1月20日公告，控股子公司复宏汉霖收到国家药品监督管理局关于同意HLX701（重组人SIRPα-IgG4Fc融合蛋白注射液）联合西妥昔单抗和化疗治疗晚期结直肠癌开展Ⅰb/Ⅱ期临床试验的批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601203624726698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","02196","BK1515","BK0239","600196","BK0187","BK0196","BK0188","BK1191","BK0183","BK0028","BK1593","BK0096","BK0012","BK0060"],"gpt_icon":0},{"id":"2604184161","title":"复星医药（600196）披露控股子公司部分境内未上市股份申请全流通完成中国证监会备案，01月19日股价下跌0.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604184161","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604184161?lang=zh_cn&edition=full","pubTime":"2026-01-19 17:29","pubTimestamp":1768814961,"startTime":"0","endTime":"0","summary":"截至2026年1月19日收盘，复星医药报收于27.44元，较前一交易日下跌0.54%，最新总市值为732.77亿元。近日，复星医药发布关于控股子公司部分境内未上市股份申请全流通完成中国证监会备案的公告。公告称，公司控股子公司复宏汉霖若干股东合计持有的182,645,856股境内未上市股份转为H股并在香港联交所上市的申请已完成中国证监会备案。其中，复星医药控股子公司复星新药持有的120,000,000股非上市股可转换为H股。复星医药表示目前无减持复宏汉霖股份的计划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900023508.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0012","BK0239","BK0188","BK0060","BK0187","BK0175","BK0196","BK0183","02196","600196","BK1191","BK1515","BK0096","BK1593"],"gpt_icon":0},{"id":"2603561455","title":"复星医药（600196）公司公告控股子公司激励计划实施进展，1月14日股价下跌0.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603561455","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603561455?lang=zh_cn&edition=full","pubTime":"2026-01-14 22:09","pubTimestamp":1768399757,"startTime":"0","endTime":"0","summary":"截至2026年1月14日收盘，复星医药报收于28.07元，较前一交易日下跌0.39%，最新总市值为749.59亿元。近日，复星医药发布关于控股子公司激励计划实施进展的公告。公告显示，其控股子公司复星安特金首期激励计划获修订，激励工具由期权变更为限制性股权，并设置分四期解锁条件，每期解锁比例上限为25%。2026年1月14日，复星安特金董事会确认存续有效的限制性股权为2,440,293份，对应注册资本244.0293万元，占总注册资本约2.9356%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400040959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK1515","BK0183","BK0012","BK0175","02196","BK0196","BK0239","600196","BK1191","BK0028","BK0096","BK0187","BK1593","BK0060"],"gpt_icon":0},{"id":"2603469483","title":"复星医药子公司注射用乳糖酸红霉素注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2603469483","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603469483?lang=zh_cn&edition=full","pubTime":"2026-01-14 17:55","pubTimestamp":1768384537,"startTime":"0","endTime":"0","summary":"北京商报讯1月14日，复星医药发布公告称，公司控股子公司苏州二叶制药有限公司就注射用乳糖酸红霉素的药品注册申请于近期获国家药品监督管理局受理，拟用于治疗由特定微生物敏感株引起的感染、预防风湿热初发、预防风湿热复发以及预防细菌性心内膜炎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601143619068536.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601143619068536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK0187","BK0060","BK0096","BK1593","BK0188","BK0012","BK1191","BK0175","BK0239","BK0183","BK0028","600196","BK0196","02196"],"gpt_icon":0},{"id":"2602535834","title":"每周股票复盘：复星医药（600196）参投基金完成备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2602535834","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602535834?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:14","pubTimestamp":1768068851,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，复星医药报收于27.65元，较上周的26.49元上涨4.38%。本周，复星医药1月9日盘中最高价报27.75元。本周关注点公司公告汇总：复星医药参与投资的华润（成都）医药产业股权投资基金已完成备案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600196","BK0028","BK0196","BK0187","BK1515","BK0012","BK0188","BK0183","BK1593","02196","BK0175","BK0096","BK1191","BK0060"],"gpt_icon":0},{"id":"1188983081","title":"复星医药富马酸福替尼胶囊药品注册申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1188983081","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188983081?lang=zh_cn&edition=full","pubTime":"2026-01-08 18:25","pubTimestamp":1767867916,"startTime":"0","endTime":"0","summary":"复星医药近日宣布，其研发的富马酸福替尼胶囊新药注册申请已获得国家药品监督管理局正式受理。该进展标志着该创新药物向上市迈出关键一步，有望为相关疾病治疗提供新的选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","BK0028","BK0187","BK0188","BK0183","600196","BK0239","BK0196","BK0060","BK0175","BK0096"],"gpt_icon":0},{"id":"2601357839","title":"复星医药(600196.SH)控股子公司药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2601357839","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601357839?lang=zh_cn&edition=full","pubTime":"2026-01-08 17:33","pubTimestamp":1767864812,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布公告，近日，公司控股子公司复星万邦(江苏)医药集团有限公司就丁二酸复瑞替尼胶囊(项目代号：SAF-189，申请注册分类：化药1类;简称“该新药”)再次递交的药品注册申请获国家药品监督管理局受理，本次申报适应症为用于间变性淋巴瘤激酶(ALK)阳性的局部晚期或转移性非小细胞肺癌(NSCLC)患者的治疗。该新药为创新型小分子化学药物。除本次申报适应症外，截至公告日期(即2026年1月8日)，该新药的另一适应症非小细胞肺癌(ROS1+)于中国境内(不包括中国港澳台地区)也已完成II期临床研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390418.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600196","BK1191","BK0183","BK1593","02196","BK0060","BK0187","BK0188","BK0239","BK0012","BK0175","BK0096","BK1515","BK0028","BK0196"],"gpt_icon":0},{"id":"2601300279","title":"复星医药（600196）披露参与设立之私募股权投资基金进展，1月5日股价上涨2.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601300279","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601300279?lang=zh_cn&edition=full","pubTime":"2026-01-05 17:43","pubTimestamp":1767606194,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，复星医药报收于27.27元，较前一交易日上涨2.94%，最新总市值为728.23亿元。该股当日开盘26.58元，最高27.28元，最低26.58元，成交额达7.07亿元，换手率为1.24%。近日，复星医药发布关于参与设立之私募股权投资基金进展的公告。转让后，基金认缴规模仍为50,000万元，复星医药控股子公司大连复健、宁波复瀛合计认缴比例维持51%不变。大连引导基金成为新有限合伙人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500025831.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0187","BK1593","02196","BK0188","BK0096","BK0183","600196","BK0196","BK0012","BK0028","BK1191","BK1515","BK0175","BK0060"],"gpt_icon":0},{"id":"2601024470","title":"14亿元接盘“不良资产” 复星医药被质疑“豪赌”","url":"https://stock-news.laohu8.com/highlight/detail?id=2601024470","media":"经济参考报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601024470?lang=zh_cn&edition=full","pubTime":"2026-01-05 04:50","pubTimestamp":1767559813,"startTime":"0","endTime":"0","summary":"2025年末，复星医药（600196.SH）抛出一项交易总额高达14.12亿元的收购方案，医药领域专业人士却直呼“看不懂”——一款原本在医药界都备受争议的产品，复星医药为何还要重金收购？由于标的公司品种因注册批件到期暂停销售，复星医药的收购也引来了上交所的监管问询。尽管复星医药随后进行回复并于12月30日举行对外投资事项说明会，但仍未打消市场疑虑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601053608050852.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601053608050852.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["600196","BK1593","02196","BK0060","BK1515","BK0187","BK0183","BK0028","BK0012","BK0096","BK0196","BK1191","BK0175","BK0239","BK0188"],"gpt_icon":0},{"id":"2600036920","title":"每周股票复盘：复星医药（600196）SRT-007启动Ⅰ期临床，研发已投3219万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2600036920","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600036920?lang=zh_cn&edition=full","pubTime":"2026-01-02 02:59","pubTimestamp":1767293948,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，复星医药报收于26.89元，较上周的27.27元下跌1.39%。本周，复星医药12月22日盘中最高价报27.33元。该项目截至2025年11月累计研发投入约3,219万元。该药品尚需完成临床研究并经审批后方可上市，研发过程存在不确定性。股本股东变化截至2025年12月31日，复星医药普通股H股和A股的法定注册资本、已发行股份及库存股份数目均无变动。2025年A股期权计划项下88,700份期权失效，H股受限制股份单位计划下207,300份单位失效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000752.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02196","BK0060","BK0196","BK0012","BK0175","600196","BK0028","BK0239","BK0183","BK1191","BK1593","BK0187","BK0188","BK1515","BK0096"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1769722702673,"stockEarnings":[{"period":"1week","weight":-0.0048},{"period":"1month","weight":0.0249},{"period":"3month","weight":-0.0712},{"period":"6month","weight":-0.0046},{"period":"1year","weight":0.1527},{"period":"ytd","weight":0.0238}],"compareEarnings":[{"period":"1week","weight":0.0086},{"period":"1month","weight":0.0486},{"period":"3month","weight":0.0514},{"period":"6month","weight":0.168},{"period":"1year","weight":0.2791},{"period":"ytd","weight":0.0477}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","registeredCapital":"267042万元","survey":" 上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。","listedPrice":7.15},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,600196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}